Abstract
DNA methylation is recognized as one of several epigenetic regulators of gene expression and as potential driver of carcinogenesis through gene-silencing of tumor suppressors and activation of oncogenes. However, abnormal methylation, even of promoter regions, does not necessarily alter gene expression levels, especially if the gene is already silenced, leaving the exact mechanisms of methylation unanswered. Using a large cohort of matching DNA methylation and gene expression samples of colorectal cancer (CRC; n = 77) and normal adjacent mucosa tissues (n = 108), we investigated the regulatory role of methylation on gene expression. We show that on a subset of genes enriched in common cancer pathways, methylation is significantly associated with gene regulation through gene-specific mechanisms. We built two classification models to infer gene regulation in CRC from methylation differences of tumor and normal tissues, taking into account both gene-silencing and gene-activation effects through hyper- and hypo-methylation of CpGs. The classification models result in high prediction performances in both training and independent CRC testing cohorts (0.92<AUC<0.97) as well as in individual patient data (average AUC = 0.82), suggesting a robust interplay between methylation and gene regulation. Validation analysis in other cancerous tissues resulted in lower prediction performances (0.69<AUC<0.90); however, it identified genes that share robust dependencies across cancerous tissues. In conclusion, we present a robust classification approach that predicts the gene-specific regulation through DNA methylation in CRC tissues with possible transition to different cancer entities. Furthermore, we present HMGA1 as consistently associated with methylation across cancers, suggesting a potential candidate for DNA methylation targeting cancer therapy.
| Original language | English |
|---|---|
| Journal | Epigenetics |
| Volume | 13 |
| Issue number | 4 |
| Pages (from-to) | 386-397 |
| Number of pages | 12 |
| ISSN | 1559-2294 |
| DOIs | |
| Publication status | Published - 03.04.2018 |
Funding
We are grateful to Dr. Melanie Bewerunge-Hudler and the Genomics and Proteomics Core Facility at the German Cancer Research Center (Heidelberg, Germany) for running the Illumina Infinium HumanMethyla-tion450 BeadChip microarrays, the Illumina Human HT-12 Whole-Genome Expression Bead Chips and related services. The ColoCare Study and Consortium has been designed and first implemented at the Fred Hutchinson Cancer Research Center, Seattle, USA (PIs: Ulrich/Grady) and protocols have been used with permission in Heidelberg, Germany (PI: Ulrich). The ColoCare Study site in Heidelberg has been funded by the Matthias Lackas Foundation, the German Cancer Consortium (DKTK) and the Division of Preventive Oncology at the German Cancer Research Center (DKFZ). Hagen Klett and Melanie Boerries were additionally funded by the German Ministry of Education and Research (BMBF) within the e:Med consortium “DeCaRe-Delineating Cardiac Regeneration”. Hauke Busch acknowledges support through the Excellence cluster EXC 306 “Inflammation at Interfaces” of the German Science Foundation (DFG) and Melanie Boerries the collaborative research center (CRC) 850, project Z1 and C9. Finally, we would like to thank Andreas Hecht for critically reviewing the manuscript and providing feedback.